TY - JOUR
T1 - Curcumin for Parkinson´s disease
T2 - Potential therapeutic effects, molecular mechanisms, and nanoformulations to enhance its efficacy
AU - Cortés, Hernán
AU - Reyes-Hernández, Octavio D.
AU - Gonzalez-Torres, Maykel
AU - Vizcaino-Dorado, Pablo A.
AU - Del Prado-Audelo, Maria Luisa
AU - Alcalá-Alcalá, Sergio
AU - Sharifi-Rad, Javad
AU - Figueroa-González, Gabriela
AU - González-Del Carmen, Manuel
AU - Florán, Benjamín
AU - Leyva-Gómez, Gerardo
N1 - Publisher Copyright:
Copyright: © 2021 by the C.M.B. Association. All rights reserved.
PY - 2021/1/31
Y1 - 2021/1/31
N2 - Parkinson's disease (PD) is one of the most prevalent neurodegenerative disorders worldwide. It is caused by the degeneration of dopaminergic neurons from the substantia nigra pars compacta. This neuronal loss causes the dopamine deficiency that leads to a series of functional changes within the basal ganglia, producing motor control abnormalities. L-DOPA is considered the gold standard for PD treatment, and it may alleviate its clinical manifestations for some time. However, its prolonged administration produces tolerance and several severe side effects, including dyskinesias and gastrointestinal disorders. Thus, there is an urgent need to find effective medications, and current trends have proposed some natural products as emerging options for this purpose. Concerning this, curcumin represents a promising bioactive compound with high therapeutic potential. Diverse studies in cellular and animal models have suggested that curcumin could be employed for the treatment of PD. Therefore, the objective of this narrative mini-review is to present an overview of the possible therapeutic effects of curcumin and the subjacent molecular mechanisms. Moreover, we describe several possible nanocarrier-based approaches to improve the bioavailability of curcumin and enhance its biological activity.
AB - Parkinson's disease (PD) is one of the most prevalent neurodegenerative disorders worldwide. It is caused by the degeneration of dopaminergic neurons from the substantia nigra pars compacta. This neuronal loss causes the dopamine deficiency that leads to a series of functional changes within the basal ganglia, producing motor control abnormalities. L-DOPA is considered the gold standard for PD treatment, and it may alleviate its clinical manifestations for some time. However, its prolonged administration produces tolerance and several severe side effects, including dyskinesias and gastrointestinal disorders. Thus, there is an urgent need to find effective medications, and current trends have proposed some natural products as emerging options for this purpose. Concerning this, curcumin represents a promising bioactive compound with high therapeutic potential. Diverse studies in cellular and animal models have suggested that curcumin could be employed for the treatment of PD. Therefore, the objective of this narrative mini-review is to present an overview of the possible therapeutic effects of curcumin and the subjacent molecular mechanisms. Moreover, we describe several possible nanocarrier-based approaches to improve the bioavailability of curcumin and enhance its biological activity.
KW - Curcumin
KW - Nanoparticles
KW - Natural products
KW - Neurodegeneration
KW - Neurodegenerative diseases
KW - Parkinson´s disease
UR - https://www.scopus.com/pages/publications/85103237944
U2 - 10.14715/cmb/2021.67.1.15
DO - 10.14715/cmb/2021.67.1.15
M3 - Artículo
C2 - 34817361
AN - SCOPUS:85103237944
SN - 0145-5680
VL - 67
SP - 101
EP - 105
JO - Cellular and Molecular Biology
JF - Cellular and Molecular Biology
IS - 1
ER -